Free Trial
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Fulcrum Therapeutics logo
$7.00 +0.07 (+1.07%)
As of 07/3/2025 01:43 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Key Stats

Today's Range
$6.65
$6.95
50-Day Range
$3.53
$7.38
52-Week Range
$2.32
$10.13
Volume
146,358 shs
Average Volume
915,507 shs
Market Capitalization
$378.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.29
Consensus Rating
Moderate Buy

Company Overview

Fulcrum Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

FULC MarketRank™: 

Fulcrum Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 2752nd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Fulcrum Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Fulcrum Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fulcrum Therapeutics is -100.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fulcrum Therapeutics is -100.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fulcrum Therapeutics has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Fulcrum Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    11.59% of the float of Fulcrum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulcrum Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fulcrum Therapeutics has recently increased by 2.46%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Fulcrum Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Fulcrum Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.59% of the float of Fulcrum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Fulcrum Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fulcrum Therapeutics has recently increased by 2.46%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Fulcrum Therapeutics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for FULC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,520.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Fulcrum Therapeutics is held by insiders.

  • Percentage Held by Institutions

    89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fulcrum Therapeutics' insider trading history.
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FULC Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

FULC Stock Analysis - Frequently Asked Questions

Fulcrum Therapeutics' stock was trading at $4.70 at the beginning of 2025. Since then, FULC shares have increased by 49.0% and is now trading at $7.0040.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) issued its quarterly earnings data on Thursday, May, 1st. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01.
Read the conference call transcript
.

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/01/2025
Today
7/04/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.29
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-10.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.73 million
Pretax Margin
-0.64%

Debt

Sales & Book Value

Annual Sales
$80 million
Price / Cash Flow
N/A
Book Value
$4.51 per share
Price / Book
1.55

Miscellaneous

Free Float
50,200,000
Market Cap
$378.08 million
Optionable
Optionable
Beta
2.37
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:FULC) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners